U.S. Blood Group Typing Market Size, Share & COVID-19 Impact Analysis, By Product (Instruments and Reagents & Kits), By Test Type (ABO Tests, Antigen Typing, Antibody Screening, Cross-matching Tests, and HLA Typing), By Technique (Serology Tests and Molecular Tests), By End-user (Hospital-based Laboratories and Independent Laboratories & Blood Banks), and Country Forecast, 2023-2030

The U.S. blood group typing market size was worth USD 611.0 million in 2022 and is projected to grow at a CAGR of 7.3% during the forecast period.

In recent years, the U.S. is witnessing an increasing number of organ transplant procedures being performed in the country. According to the data published by the United Network for Organ Sharing, in 2022, more than 42,800 organ transplants were performed in the U.S. This number has significantly increased over the years. However, a large number of individuals are on the national transplant waiting list. As blood group typing is the first important test in determining the compatibility of donor and recipient’s blood, it plays an important role in organ transplant procedures. Thus, the high demand for organ transplantation is majorly driving market growth.

Furthermore, the demand for blood group typing products is also increasing in blood banks as these entities play an important role in blood storage. To avoid transfusion reactions, the blood is required to be screened thoroughly. The growing trend of blood donation and increasing awareness among the population is anticipated to drive market growth.

The recent COVID-19 pandemic negatively impacted the market growth majorly due to decreased blood donations and transfusions across the country. Several market players also witnessed a decline in their revenues as a result of the pandemic.

LATEST TRENDS

Increasing Demand for Automated Blood Group Typing Technologies to Boost Market Growth

In recent years, with the growing demand for advanced products, market players have been focusing on the development of innovative products based on automated blood group typing technologies, such as Polymerase Chain Reaction (PCR)-based and microarray techniques. These technologies offer enhanced test speed, standardization, and safety of transfusion diagnostics.

Additionally, several benefits offered by automated blood typing, such as reduced cost, time, & errors and improved efficiency, are driving the demand for these tests among end-user. These factors have boosted the demand for automated blood group typing technologies, which is driving the market growth of the U.S. market.

DRIVING FACTORS

Increased Blood Donations in the U.S. Set to Drive Market Expansion

In the U.S., a notable increase in the number of blood donations has been witnessed in recent years. This has accelerated the demand for cross-matching and blood group recognition processes. Additionally, increasing cases of road accidents and trauma-inducing incidents also resulted in increased use of blood group typing procedures.  The confluence of these factors is anticipated to drive the U.S. blood group typing market growth in the coming years.  

Furthermore, the increasing need for blood and blood components for many surgical as well as medical applications has boosted voluntary blood donations in the U.S. To cater for this demand, the government is also undertaking various initiatives to increase awareness among the general population.

According to the American National Red Cross, in the U.S., around 6,500 units of plasma and 5,000 units of platelets are required daily.

RESTRAINING FACTORS

Blood Supply Challenges to Impede Growth Prospects

In January 2022, the first-ever national blood crisis was declared by the American Red Cross. The country is facing a severe shortage of blood to fulfill the growing demand for surgeries and other medical applications. Due to the pandemic, many medical procedures and treatments were postponed by the patients, which resulted in more advanced stages of diseases being treated now.

Additionally, aspects, such as drug overdose, increase in gun violence, and road accidents also demand blood in high volumes. However, the limited availability of blood in the country hampers the use of blood group typing products, in turn, restraining the growth of the market. 

SEGMENTATION

By Product Analysis

Based on the product, the market is divided into instruments and reagents & kits.

In 2022, the reagents & kits segment captured the highest market share of the U.S. market. The increasing number of blood transfusions & blood donations is increasing the demand for reagents & kits in the country. This, along with the repetitive purchases and comparatively less prices of reagents & kits, is fueling segment growth.

The instruments segment is anticipated to witness a notable growth over the forecast period. The growing demand for technologically advanced products led to the launch of instruments, in turn, driving the segment's growth.

By Test Type Analysis

On the basis of test type, the market is divided into antigen typing, ABO tests, cross-matching tests, antibody screening, and HLA typing.

The antibody screening segment accounted for the largest U.S. blood group typing market share in 2022. The increasing patient population suffering chronic diseases, increased demand for blood transfusions, and high volume of prenatal testing are some of the factors contributing to the segment growth. Key industry players focusing on new product launches and approvals for these procedures, is fueling segment growth.

The ABO test segment accounted for the second-largest share in 2022. This can be attributed to the high usage of this test in transplant procedures, which would propel the segment growth. ABO test is usually conducted to provide a comprehensive blood typing profile in turn enhancing compatibility assessment.

By Technique Analysis

Based on technique, the market is bifurcated into serology tests and molecular tests.

The serology tests segment seized the dominating position in the market in 2022. This method is traditional and commonly preferred for blood group typing tests in laboratories. Additionally, benefits offered by these tests, such as being easy to perform and readily available, boost the adoption of these tests among the end-users.

The molecular tests segment is anticipated to witness substantial growth over the projected period. The rising demand for these tests for typing a wide spectrum of minor blood group antigens is responsible for the growth of this segment.

By End-user Analysis

In terms of end-user, the market is segmented into hospital-based laboratories and independent laboratories & blood banks.

In 2022, the independent laboratories & blood banks segment dominated the market in the U.S. A key factor supporting the segment’s growth include the high number of blood group typing procedures being performed in these facilities. In addition, expanding the network of various independent laboratories is also driving segment growth.

The hospital-based laboratories segment is estimated to grow sizably over the forecast period. The growing number of organ transplantation procedures in hospitals across the country is expected to boost segment growth.

KEY INDUSTRY PLAYERS

The competitive marketplace for the U.S. blood group typing market shows a moderately fragmented structure. Leading entities, such as QuidelOrtho Corporation, Grifols S.A., and Bio-Rad Laboratories, dominate the U.S. market with a significant share. A strong distribution network across the country, coupled with a focus on constant new product approval and launches, has resulted in the dominating position of these companies.

• For instance, in September 2021, QuidelOrtho Corporation introduced New ISXM capabilities on its ORTHO VISION MAX and ORTHO VISION analyzers.

Some other major players that are operating in the U.S. market include CareDx Inc., Agena Bioscience, Inc., Quotient Limited, Thermo Fisher Scientific Inc., and others. These companies are focusing on various strategies to expand their market presence.

LIST OF KEY COMPANIES PROFILED:

• Quotient Limited (Switzerland)


• CareDx Inc. (U.S.)


• Agena Bioscience, Inc. (Mesa Laboratories, Inc.) (U.S.)


• DIAGAST (U.S.)


• Illumina, Inc. (U.S.)


• Grifols, S.A. (Spain)


• Immucor, Inc. (U.S.)


• Bio-Rad Laboratories, Inc. (U.S.)


• Thermo Fisher Scientific Inc. (U.S.)


• Merck KGaA (Germany)


• QIAGEN (Netherlands)


• Beckman Coulter, Inc. (Danaher) (U.S.)


• QuidelOrtho Corporation (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• July 2022: Quotient Limited and InfYnity Biomarkers signed an agreement for the expansion of MosaiQ's infectious disease portfolio, including blood screening tests.


• March 2021: Grifols S.A. installed a DG Reader Net semi-automated analyzer at ThedaCare Medical Center-Wild Rose in Wisconsin, U.S. This product is used for pre-transfusion blood type compatibility testing.


• October 2020: Lorne Laboratories, a company producing blood grouping reagents and diagnostic test kits for medical use, was acquired by Calibre Scientific.

REPORT COVERAGE

The market research report provides a detailed analysis of the market. It focuses on key market segments such as product, gender, and procedure. Additionally, it includes detailed insights on market dynamics, technological advancements in blood group typing, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. The report also provides the competitive landscape of the key companies at the U.S. level.

Report Scope & Segmentation